Search results for "carcinogenesis"

showing 10 items of 6434 documents

Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): A study protocol for a multicentre longitudinal interve…

2021

IntroductionThe number of gynaecological cancer survivors is increasing and there is a need for a more sustainable model of follow-up care. Today’s follow-up model is time-consuming and patients have reported unmet needs regarding information about their cancer and strategies for managing the consequences of treatment. The main aim of this study is to assess health-related empowerment—in terms of patient education, psychosocial support, and promotion of physical activity—in a new follow-up model by comparing it to standard follow-up in a quasi-randomised study involving intervention hospitals and control hospitals.Methods and analysisAt the intervention hospitals, patients will be stratifie…

protocols & guidelinesSurvivorship0302 clinical medicineinformation technologyHealth careMulticenter Studies as Topichealth economics030212 general & internal medicine1506Empowermentmedia_commonBiological Specimen BanksRandomized Controlled Trials as TopicRHealth technologyPublic Health Global Health Social Medicine and EpidemiologyGeneral MedicineBiobankOncologyVDP::Medisinske Fag: 700::Helsefag: 800030220 oncology & carcinogenesisCancer treatmentMedicineFemale1717Hälso- och sjukvårdsorganisation hälsopolitik och hälsoekonomimedicine.medical_specialtyGenital Neoplasms Femalemedia_common.quotation_subjectHealth-related empowermentBiomedical Technologyquality in health care03 medical and health sciencesQuality of life (healthcare)medicineHumansLife StyleConsequencesGynaecological cancerHealth economicsbusiness.industryVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762gynaecological oncologychange managementRepeated measures designHealth Care Service and Management Health Policy and Services and Health EconomyVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762Folkhälsovetenskap global hälsa socialmedicin och epidemiologiFamily medicineQuality of LifeFollow-up careNeoplasm Recurrence LocalbusinessPatient education
researchProduct

Structured reporting of rectal cancer staging and restaging: A consensus proposal

2021

Background: Structured reporting (SR) in oncologic imaging is becoming necessary and has recently been recognized by major scientific societies. The aim of this study was to build MRI-based structured reports for rectal cancer (RC) staging and restaging in order to provide clinicians all critical tumor information. Materials and Methods: A panel of radiologist experts in abdominal imaging, called the members of the Italian Society of Medical and Interventional Radiology, was established. The modified Delphi process was used to build the SR and to assess the level of agreement in all sections. The Cronbach’s alpha (Cα) correlation coefficient was used to assess the internal consistency of ea…

re-stagingCancer Researchmedicine.medical_specialtyStagingColorectal cancerIntraclass correlationModified delphiArticle030218 nuclear medicine & medical imaging03 medical and health sciencesRe‐staging0302 clinical medicineMagnetic resonance imagingmagnetic resonance imaging; rectal cancer; re‐staging; staging; structured reportingCronbach's alphaStructured reportingInternal consistencymedicineMedical physicsRectal cancerRC254-282Final versionmedicine.diagnostic_testbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensInterventional radiologymedicine.diseaseOncology030220 oncology & carcinogenesisbusinessStructured reporting
researchProduct

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group…

2021

Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex

renal failurekidneyendocrine systemCancer Researchmedicine.medical_specialtyCyclophosphamide030232 urology & nephrologyUrologyRenal functionlcsh:RC254-282NiereninsuffizienzArticleBortezomib03 medical and health sciences0302 clinical medicineMultiple myelomamedicineddc:610Renal insufficiencyLenalidomideDexamethasoneMultiple myelomaLenalidomideKidneybusiness.industryBortezomiblcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensinduction regimenmedicine.disease3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisPlasmozytombusinessDDC 610 / Medicine & healthKidney diseasemedicine.drugCancers
researchProduct

Rho GTPases are over-expressed in human tumors.

1999

Small GTPases of the Rho family are involved in the regulation of a variety of cellular processes, such as the organization of the microfilamental network, cell-cell contact and malignant transformation. To address the question of whether Rho proteins are involved in carcinogenesis in man, we compared their expression in tumors from colon, breast and lung with that of the corresponding normal tissue originating from the same patient. As shown by Rho-specific 32P-ADP-ribosylation, as well as Western-blot analysis, the amount of RhoA protein was largely increased in all 3 types of tumors tested. The most dramatic differences in the expression of Rho GTPases were observed in breast tissue. All…

rho GTP-Binding ProteinsCancer ResearchPathologymedicine.medical_specialtyRHOALung NeoplasmsColonBreast NeoplasmsCell Cycle ProteinsGTPaseCDC42medicine.disease_causeMalignant transformationGTP PhosphohydrolasesGTP-Binding ProteinsmedicineHumansrho-Specific Guanine Nucleotide Dissociation InhibitorsBreastcdc42 GTP-Binding ProteinrhoB GTP-Binding ProteinLungGuanine Nucleotide Dissociation InhibitorsMitogen-Activated Protein Kinase 1Adenosine Diphosphate RibosebiologyCancerMembrane Proteinsmedicine.diseaseImmunohistochemistryrac GTP-Binding ProteinsOncologyrhoC GTP-Binding ProteinCalcium-Calmodulin-Dependent Protein KinasesColonic Neoplasmsbiology.proteinCancer researchImmunohistochemistryCarcinogenesisrhoA GTP-Binding ProteinRhoC GTP-Binding ProteinInternational journal of cancer
researchProduct

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in De…

2020

Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Methods: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. Results: O…

safetyAdultMalemedicine.medical_specialtyTime Factorsbiologic agentsprospective cohortlong-term follow-upDermatologyimmunosuppressive agentsanti-inflammatory agentsCohort Studies030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinePsoriasisUstekinumabmedicineAdalimumabHumansPsoriasisRegistriesAdverse effectProspective cohort studyAgedbusiness.industryregistriespsoriasis/drug therapyanti-TNFMiddle Agedmedicine.diseaseInfliximabBiological TherapySpain030220 oncology & carcinogenesispharmacovigilanceadverse effectsSecukinumabFemaleApremilastbusinessmedicine.drugJournal of the American Academy of Dermatology
researchProduct

Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor

2020

Introduction: The discovery and the clinical availability of novel cyclin-dependent kinases 4 and 6 inhibitors have profoundly changed the therapeutic scenario of metastatic hormone receptor-positive breast carcinoma. Among these inhibitors, abemaciclib can induce potent and sustained cell cycle arrest and immune system stimulation. Areas covered: This review summarizes the safety profile and clinical efficacy data on abemaciclib alone or in combination with aromatase inhibitors or fulvestrant in metastatic hormone receptor-positive breast carcinoma. The management of patients treated with abemaciclib is the object of this paper. Expert opinion: As shown in phase 2 and 3 clinical trials on …

safetyAminopyridinesBreast Neoplasms030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundabemaciclib breast cancer metastases hormonal receptors safetybreast cancer0302 clinical medicineBreast cancerCyclin-dependent kinaseAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)metastasesskin and connective tissue diseasesFulvestrantProtein Kinase InhibitorsAbemaciclibbiologyAromatase Inhibitorsbusiness.industryKinasehormonal receptorsCyclin-Dependent Kinase 4Cell Cycle CheckpointsCyclin-Dependent Kinase 6General Medicinemedicine.diseaseAbemaciclibchemistry030220 oncology & carcinogenesisQuality of LifeCancer researchbiology.proteinBenzimidazolesFemalesense organsbusinessHormone
researchProduct

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

2016

Purpose The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study segment. Patients and methods Patients with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 intramuscular injections of the PRAME immunotherapeutic. The RecPRAME dose was 20, 100 or 500 µg in cohorts 1, 2 and 3, respectively, with a fixed dose of AS15. Advers…

safetyCancer Researchmedicine.drug_classmedicine.medical_treatmentMedizinPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerimmunogenicityImmunostimulant03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerCancer immunotherapymedicine1506030304 developmental biologyOriginal ResearchPRAME antigen0303 health sciencesPRAMEcancer immunotherapybusiness.industryMelanomaImmunogenicityCancermedicine.disease3. Good healthOncology030220 oncology & carcinogenesisImmunologyChillsmedicine.symptombusinessmetastatic melanoma
researchProduct

Polyphenols and Pharmacological Screening of a Monarda fistulosa L. dry Extract Based on a Hydrodistilled Residue By-Product

2021

This study aimed to determine the composition and content of polyphenols in the dry extract obtained from the hydrodistilled residue by-product of the wild bergamot (Monarda fistulosa L., Lamiaceae Martinov family) herb (MFDE) and to evaluate its safety and pharmacological properties. The total phenolic content (TPC) in the MFDE was 120.64 mg GAE/g. The high-performance liquid chromatography (HPLC) analysis showed the presence of a plethora of phenolic compounds, including hydroxycinnamic acids and flavone derivatives in the MFDE, with rosmarinic acid and luteolin-7-O-glucoside being the main components. With an IC50 value of 0.285 mg/mL, it was found to be a strong DPPH radical scavenger. …

safetyDPPHRM1-950phenolic compoundsMonarda fistulosa01 natural sciencesHigh-performance liquid chromatographywild bergamot03 medical and health scienceschemistry.chemical_compound0302 clinical medicineantiradical activityPharmacology (medical)anti-inflammatory activityanalgesic activityOriginal ResearchPharmacologyResidue (complex analysis)biologyTraditional medicine010405 organic chemistryRosmarinic acidbiology.organism_classificationAcute toxicity0104 chemical scienceschemistryherbPolyphenol030220 oncology & carcinogenesispostdistillation wasteLamiaceaeTherapeutics. PharmacologyFrontiers in Pharmacology
researchProduct

Tenapanor for the treatment of irritable bowel syndrome with constipation.

2020

Introduction: Irritable bowel syndrome with constipation is associated with higher rates of functional impairment, as compared to other subtypes of the syndrome. Conventional laxative-based pharmacologic therapy of IBS-C, which is mostly symptom-based, is often unsatisfactory. Tenapanor represents a first-in-class orally available inhibitor of NHE3, which is minimally absorbed in the GI tract, what constitutes a significant therapeutic benefit, as it may act on the drug target. Areas covered: Aim of this article is to sum up the evidences about pharmacodynamics and pharmacokinetics of tenapanor, focusing on animal models and in vitro studies, but also discuss clinical trials on tenapanor's …

safetymedicine.medical_specialtyFunctional impairmentConstipationmedicine.medical_treatmentefficacyLaxative030226 pharmacology & pharmacyGastroenterologyIrritable Bowel Syndrome03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGastrointestinal AgentsInternal medicinemedicineAnimalsHumansPharmacology (medical)Pharmacologic therapyDrug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsTenapanorIrritable bowel syndromeSulfonamidesbusiness.industrySodium-Hydrogen Exchanger 3General Medicinemedicine.diseaseIsoquinolinestenapanor.chemistry030220 oncology & carcinogenesismedicine.symptombusinessConstipationExpert review of clinical pharmacology
researchProduct

Bcl-xL as a Modulator of Senescence and Aging

2021

Many features of aging result from the incapacity of cells to adapt to stress conditions. When cells are overwhelmed by stress, they can undergo senescence to avoid unrestricted growth of damaged cells. Recent findings have proven that cellular senescence is more than that. A specific grade of senescence promotes embryo development, tissue remodeling and wound healing. However, constant stresses and a weakening immune system can lead to senescence chronicity with aging. The accumulation of senescent cells is directly related to tissue dysfunction and age-related pathologies. Centenarians, the most aged individuals, should accumulate senescent cells and suffer from their deleterious effects,…

senescenceReviewmedicine.disease_causelcsh:Chemistry0302 clinical medicineImmunologic Surveillancelcsh:QH301-705.5SpectroscopyCellular Senescenceimmunosenescence0303 health sciencesapoptosisGeneral MedicineImmunosenescenceComputer Science ApplicationsCell biologyOrgan Specificity030220 oncology & carcinogenesisDisease SusceptibilitycentenariansProtein BindingSignal TransductionSenescencebcl-X ProteinBcl-xLBiologyCatalysisInorganic Chemistry03 medical and health sciencesImmune systemStress PhysiologicalmedicineAnimalsHumansPhysical and Theoretical ChemistrySenolyticMolecular Biology030304 developmental biologyBcl-xLOrganic ChemistryIntrinsic apoptosisagingGene Expression Regulationlcsh:Biology (General)lcsh:QD1-999senolyticsbiology.proteinWound healingOxidative stressBiomarkersDNA DamageInternational Journal of Molecular Sciences
researchProduct